WASHINGTON — The Trump administration is actively negotiating new drug-pricing agreements with smaller pharmaceutical companies, as reported by multiple sources familiar with the discussions, including a White House official.
This initiative provides an avenue for smaller firms—previously excluded from earlier negotiations—to commit to lower pricing structures, potentially shielding themselves from impending tariffs and new Medicare pricing policies. The administration’s approach mirrors its strategy with larger pharmaceutical companies, aiming to secure voluntary, confidential agreements that promote reduced prices and increased domestic manufacturing.
These negotiations are particularly significant for smaller players in the pharmaceutical sector, who have been navigating considerable uncertainty regarding the impact of federal policies on their operations. The opportunity to engage in these discussions not only allows them to secure more favorable pricing terms but also offers a clearer understanding of their regulatory landscape moving forward.
Use the database as your supply chain compass →
